160 related articles for article (PubMed ID: 8570306)
1. Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.
Dasgupta B; Tomkiewicz RP; Boyd WA; Brown NE; King M
Pediatr Pulmonol; 1995 Aug; 20(2):78-82. PubMed ID: 8570306
[TBL] [Abstract][Full Text] [Related]
2. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
3. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
Dasgupta B; King M
Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
[TBL] [Abstract][Full Text] [Related]
4. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
Dasgupta B; Brown NE; King M
Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
7. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
Feng W; Garrett H; Speert DP; King M
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials of recombinant human DNase in cystic fibrosis patients.
Aitken ML
Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
[TBL] [Abstract][Full Text] [Related]
9. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Hodson ME
Eur Respir J; 1996 Mar; 9(3):531-4. PubMed ID: 8730015
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
11. Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis.
Henry RL; Gibson PG; Carty K; Cai Y; Francis JL
Pediatr Pulmonol; 1998 Aug; 26(2):97-100. PubMed ID: 9727759
[TBL] [Abstract][Full Text] [Related]
12. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
Griese M; App EM; Duroux A; Burkert A; Schams A
Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
15. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
16. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
17. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
18. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
19. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
20. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase.
Brandt T; Breitenstein S; von der Hardt H; Tümmler B
Thorax; 1995 Aug; 50(8):880-2. PubMed ID: 7570441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
